Please note that assistive links (commonly known as "skip to links") are used throughout this site. These links are not well-supported by some mobile devices. If you are encountering difficulty using these links, please navigate around these links, or access the site on a desktop browser.
Skip to the primary content of this page Skip to the footer of this page
Provident Healthcare Partners Provident Healthcare Partners

Q3 2024 CCO Update

Provident Healthcare Partners
Skip to the end of the Expertise Menu

Q3 2024 CCO Update

Q3-2024 presented similar transaction volume to the second quarter of the year, and heightened levels relative to 2023 activity. Following the Federal Reserve’s September rate cut, more favorable capital markets and increased private equity interest continue to lay a foundation for accelerated add-on activity and additional platform creations.

As global lending markets continue to open with more favorable pricing, pharmaceutical companies and biotech operators are likely to take advantage of borrowing conditions to finance expansion and invest in drug development initiatives, thereby increasing the demand for outsourced commercialization services. In response, commercialization firms are striving to differentiate themselves by specializing in niche areas that will attract reliable wallet share from pharmaceutical and biotech clients. M&A will continue to play a critical role as companies pursue strategic partnerships aimed at creating integrated, full-service models in an increasingly competitive market.

To print and download the full CCO Update report, please click below…

[holo_button icon=”/wp-content/uploads/2024/10/Q3-2024-CCO-Newsletter_vP.pdf”” color=”#003561″ target=”blank”]PRINT/DOWNLOAD[/holo_button]